Recently, Suzhou Junjing Biopharmaceutical Technology Co., Ltd., a subsidiary of the company, received the notice of approval of Drug Clinical Trials approved and issued by the State Drug Administration, and the application for clinical trials of the fourth generation EGFR inhibitor WJ13404 tablets (project code "JS113") was approved.
君实生物(01877.HK):第四代EGFR抑制剂WJ13404片临试申请获得批准
Jun Shi Bio (01877.HK): the application for the fourth generation EGFR inhibitor WJ13404 tablets was approved
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.